Man Group PLC Madrigal Pharmaceuticals, Inc. Transaction History

Man Group PLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$146.04 - $225.78 $322,164 - $498,070	2,206 Added 11.44%	21,487 $3.14 Million
Q2 2023 Aug 14, 2023	BUY	$203.88 - $312.0 $3.93 Million - $6.02 Million	19,281 New	19,281 $4.45 Million
Q3 2022 Nov 14, 2022	BUY	$60.57 - $79.51 $460,332 - $604,276	7,600 New	7,600 $494,000
Q1 2022 May 16, 2022	SELL	$55.89 - $101.89 $1.05 Million - $1.91 Million	-18,700 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$97.2 - $137.59 $447,120 - $632,914	4,600 Added 32.62%	18,700 $1.82 Million
Q1 2021 May 17, 2021	BUY	$108.54 - $125.2 $1.53 Million - $1.77 Million	14,100 New	14,100 $1.65 Million
Q2 2019 Aug 14, 2019	SELL	$91.13 - $142.5 $2.9 Million - $4.54 Million	-31,848 Closed	0 $0
Q1 2019 May 15, 2019	SELL	$103.48 - $143.84 $3.02 Million - $4.2 Million	-29,208 Reduced 47.84%	31,848 $3.99 Million
Q4 2018 Feb 14, 2019	BUY	$94.77 - $215.54 $2.65 Million - $6.02 Million	27,934 Added 84.34%	61,056 $6.88 Million
Q3 2018 Nov 14, 2018	BUY	$207.3 - $300.31 $2.38 Million - $3.45 Million	11,503 Added 53.21%	33,122 $7.09 Million
Q2 2018 Aug 14, 2018	BUY	$101.55 - $313.9 $2.2 Million - $6.79 Million	21,619 New	21,619 $6.05 Million

297

22M

819K

640K

Ticker MDGL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 17,103,400
Market Cap $5.37B
Description
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III c...

Get notified when there are updates to the investment portfolio of Man Group PLC, based on Form 13F filings with the SEC.

Stay updated on Man Group PLC with notifications on news.